On Friday, Johnson & Johnson issued an official statement and informed that they had applied for the Emergency Use Authorisation (EUA) of it's single dose COVID-19 vaccine in India.
- "On August 5,2021, Johnson & Johnson Pvt. Ltd applied for Emergency Use Authorisation (EUA) of its single-dose Covid-19 vaccine to the Government of India" read the statement.
The pharmaceutical company has claimed that their single-shot vaccine, in clinical trials, proved to be 85 per cent effective in preventing severe diseases. It also showed protection against COVID-19 related hospitalisation and death.
"The EUA submission is based on topline efficacy and safety data from the Phase 3 ensemble clinical trial, which demonstrated our single-shot vaccine was 85 per cent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalisation and death, beginning 28 days after vaccination" said Johnson & Johnson.
Earlier it was reported that the company has withdrawn its proposal of seeking approval for its single-shot vaccine but later issued a statement regarding their commitment of getting approval.
0 Comments